News Releases

AUSTIN, Texas , March 12, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies

AUSTIN, Texas , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

Milestone Triggers $10 Million Payment to Molecular Templates AUSTIN, Texas , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships AUSTIN, Texas , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of

AUSTIN, Texas , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics,

AUSTIN, Texas , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics,

AUSTIN, Texas , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for

AUSTIN, Texas , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

AUSTIN, Texas , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

- Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular